GuangYuYuan Chinese Herbal Medicine Past Earnings Performance
Past criteria checks 2/6
GuangYuYuan Chinese Herbal Medicine's earnings have been declining at an average annual rate of -54%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 4.6% per year. GuangYuYuan Chinese Herbal Medicine's return on equity is 7.3%, and it has net margins of 8.4%.
Key information
-54.0%
Earnings growth rate
-53.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -4.6% |
| Return on equity | 7.3% |
| Net Margin | 8.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How GuangYuYuan Chinese Herbal Medicine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,241 | 104 | 686 | 32 |
| 31 Dec 23 | 1,284 | 90 | 736 | 31 |
| 30 Sep 23 | 1,111 | -324 | 1,028 | 34 |
| 30 Jun 23 | 1,179 | -396 | 1,081 | 33 |
| 31 Mar 23 | 1,126 | -397 | 1,055 | 32 |
| 31 Dec 22 | 995 | -399 | 953 | 29 |
| 30 Sep 22 | 1,081 | -255 | 890 | 26 |
| 30 Jun 22 | 958 | -260 | 848 | 25 |
| 31 Mar 22 | 902 | -314 | 857 | 27 |
| 31 Dec 21 | 854 | -316 | 841 | 25 |
| 30 Sep 21 | 1,017 | -144 | 778 | 38 |
| 30 Jun 21 | 1,052 | -60 | 732 | 40 |
| 31 Mar 21 | 1,075 | 10 | 699 | 41 |
| 31 Dec 20 | 1,109 | 32 | 711 | 43 |
| 30 Sep 20 | 1,050 | 21 | 706 | 55 |
| 30 Jun 20 | 1,108 | 56 | 698 | 61 |
| 31 Mar 20 | 1,171 | 100 | 681 | 57 |
| 31 Dec 19 | 1,217 | 130 | 694 | 63 |
| 30 Sep 19 | 1,451 | 322 | 643 | 63 |
| 30 Jun 19 | 1,505 | 347 | 681 | 61 |
| 31 Mar 19 | 1,597 | 380 | 732 | 67 |
| 31 Dec 18 | 1,619 | 374 | 758 | 58 |
| 30 Sep 18 | 1,453 | 359 | 708 | 54 |
| 30 Jun 18 | 1,320 | 302 | 684 | 47 |
| 31 Mar 18 | 1,261 | 264 | 678 | 35 |
| 31 Dec 17 | 1,169 | 237 | 631 | 31 |
| 30 Sep 17 | 1,054 | 181 | 595 | 5 |
| 30 Jun 17 | 1,044 | 180 | 575 | 0 |
| 31 Mar 17 | 949 | 139 | 531 | 0 |
| 31 Dec 16 | 937 | 123 | 531 | 0 |
| 30 Sep 16 | 773 | 46 | 471 | 0 |
| 30 Jun 16 | 622 | 23 | 391 | 0 |
| 31 Mar 16 | 534 | 11 | 345 | 0 |
| 31 Dec 15 | 428 | 2 | 293 | 0 |
| 30 Sep 15 | 369 | 36 | 281 | 0 |
| 30 Jun 15 | 395 | 34 | 301 | 0 |
| 31 Mar 15 | 380 | 44 | 284 | 0 |
| 31 Dec 14 | 354 | 37 | 270 | 0 |
| 30 Sep 14 | 341 | -19 | 266 | 0 |
| 30 Jun 14 | 300 | -25 | 238 | 0 |
| 31 Mar 14 | 254 | -29 | 233 | 0 |
| 31 Dec 13 | 268 | -20 | 219 | 0 |
| 30 Sep 13 | 248 | 426 | 197 | 0 |
| 30 Jun 13 | 263 | 416 | 186 | 0 |
Quality Earnings: 600771 has high quality earnings.
Growing Profit Margin: 600771 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600771's earnings have declined by 54% per year over the past 5 years.
Accelerating Growth: 600771 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 600771 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 600771's Return on Equity (7.3%) is considered low.